SCHEMBL4548853

SCHEMBL4548853

COc1cccc(C(=O)Nc2ccc3ccc(Oc4ccnc5cc(OC)c(OC)cc45)cc3c2)c1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 3/20 0.66
MET P08581 3/20 0.64
KDR P35968 14/20 0.62
AURKA O14965 2/20 0.61
LCK P06239 2/20 0.61
TEK Q02763 2/20 0.61
AURKB Q96GD4 2/20 0.61
CSF1R P07333 1/20 0.61
BRAF P15056 1/20 0.61
FLT1 P17948 1/20 0.61
FGFR2 P21802 1/20 0.61
FLT4 P35916 1/20 0.61
CYP3A4 P08684 2/20 0.60
CYP2D6 P10635 2/20 0.60
AXL P30530 2/20 0.59
MEN1 O00255 1/20 0.58
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58
KMT2A Q03164 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2748446 0.98 PDGFRA (0.68) PDGFRAMETKDRAURKALCK
SCHEMBL2748028 0.93 PDGFRA (0.69) PDGFRAMETKDRAURKALCK
SCHEMBL4548874 0.92 KDR (0.60) PDGFRAMETKDRAURKALCK
SCHEMBL4548872 0.91 KDR (0.70) PDGFRAMETKDRAURKALCK
SCHEMBL4548863 0.91 KDR (0.70) PDGFRAMETKDRAURKALCK
SCHEMBL2747795 0.90 MET (0.75) PDGFRAMETKDRAURKALCK
SCHEMBL4548864 0.90 MET (0.60) PDGFRAMETKDRAURKALCK
SCHEMBL2749286 0.89 KDR (0.64) PDGFRAMETKDRAURKALCK
SCHEMBL2749260 0.89 MET (0.64) PDGFRAMETKDRAURKALCK
SCHEMBL4548852 0.89 KDR (0.71) PDGFRAMETKDRAURKALCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET PDGFRA 49/4885MET 3/4885KDR 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.